Table of Contents
About Dr. Jennifer Dore MD
Dr. Jennifer Dore MD is a board certified psychiatrist specializing in psychodynamic psychotherapy and medication management for conditions such as depression, anxiety, bipolar disorder, ADHD and addiction. Dr. Dore earned her MD from New York Medical College in 2007, with the highest academic distinction, Alpha Omega Alpha and holds a B.A. from Amherst College where she majored in English Literature. Upon graduating, Dr. Dore trained for three years as a surgical resident at Weill Cornell/NY Presbyterian Hospital.
Dr. Dore’s training subsequently took her to Northern California where she joined the Stanford Department of Psychiatry as a resident physician. While at Stanford, Dr. Dore’s focus included the treatment of bipolar disorder, intensive individual psychotherapy, psychopharmacology, family and couples therapy, and medical decision making. Dr. Dore’s research in the area of bipolar disorder earned her recognition from the American Psychiatric Association during their 2013 Annual Meeting in San Francisco. Dr. Dore was also elected Chief Resident for her contributions as a leader and innovator.
In 2014, Dr. Jennifer Dore founded Helios Psychiatry with a mission to serve the local Bay Area community and innovate across a broad spectrum of traditional and pioneering treatments, including Ketamine-Assisted Psychotherapy. Dr. Dore has worked with thousands of patients and published numerous research papers including, a groundbreaking study into the effects of Ketamine-Assisted Psychotherapy published in the Journal of Psychoactive Drugs. Dr. Dore has served on the board of the Ketamine Research Foundation.
Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy
The Journal of Psychoactive Drugs, March 2019
AUTHORS
Jennifer Dore, Brent Turnipseed, Shannon Dwyer, Andrea Turnipseed,Julane Andries, German Ascani, Celeste Monnette, Angela Huidekoper, Nicole Strauss, Phil Wolfson
American tertiary clinic-referred bipolar II disorder compared to bipolar I disorder: More severe in multiple ways, but less severe in a few other ways.
Dell’Osso B, et al. J Affect Disord. 2015.
Authors
Dell’Osso B1, Holtzman JN2, Goffin KC2, Portillo N2, Hooshmand F2, Miller S3, Dore J2, Wang PW2, Hill SJ2, Ketter TA4.
Trends in pharmacotherapy in patients referred to a bipolar specialty clinic, 2000-2011.
Hooshmand F, et al. J Affect Disord. 2014.
Authors
Hooshmand F1, Miller S2, Dore J1, Wang PW1, Hill SJ1, Portillo N1, Ketter TA3.
Morbidity and mortality of mucocutaneous diseases in the pediatric population at a tertiary care center.
Dore J, et al. J Burn Care Res. 2007 Nov-Dec.
Authors
A mouse herpesvirus induces relapse of experimental autoimmune arthritis by infection of the inflammatory target tissue.
Yarilin DA, et al. J Immunol. 2004.
Authors
Yarilin DA1, Valiando J [Dore], Posnett DN.
Genomic absence of the gene encoding T cell receptor Vbeta7.2 is linked to the presence of autoantibodies in Sjögren’s syndrome.
Manavalan SJ, et al. Arthritis Rheum. 2004.
Authors
Manavalan SJ1, Valiando JR [Dore], Reeves WH, Arnett FC, Necker A, Simantov R, Lyons R, Satoh M, Posnett DN.
Oligoclonal expansions of antigen-specific CD8+ T cells in aged mice.
Review article: Posnett DN, et al. Ann N Y Acad Sci. 2003.
Tumor antigen drives a persistent oligoclonal expansion of CD8+ T cells in aged mice.
Li F, et al. Eur J Immunol. 2002.
Authors
Li F1, Yarilin DA, Valiando J [Dore], Ronco A, Weksler ME, Szabo P, Posnett DN.
HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing.
Ivan M, et al. Science. 2001.
Authors
Ivan M1, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS, Kaelin WG Jr.l